OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Allergy and Clinical Immunology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
What molecular allergy teaches us about genetics and epidemiology of allergies	57
The pathogenetic role of Th17 immune response in atopic dermatitis	27
The use of environmental exposure chambers in studies related to ocular surface effects	24
The collaborative medical practice of the ocular surface: a major role of the allergist/immunologist	21
Is immunotherapy safe for treatment of severe asthma	19
Liver disease in primary antibody deficiencies	19
Anaphylaxis due to antiallergic and antiasthmatic biologics	19
Economic burden of drug-induced anaphylaxis: what can we do better?	18
E-cigarettes and asthma in adolescents	18
Chronic spontaneous urticaria: new evidences on the role of autoimmunity	18
Drug allergy awareness and perspectives with the implementation of the International Classification of Diseases-11	18
Consequences of severe asthma exacerbations	18
Bronchiectasis and obstructive lung diseases in primary antibody deficiencies and beyond: update on management and pathomechanisms	17
Real-world evidence of allergen immunotherapy	17
Mast cell conditions and drug allergy: when to suspect and how to manage	17
Update on occupational allergy, including asthma, to soluble platinum salts	17
New approaches in childhood asthma treatment	17
Atopic manifestations of inborn errors of immunity	17
Editorial introductions	16
Neuroimmune signalling pathways in chronic rhinosinusitis with nasal polyps	16
Editorial introductions	15
Ocular involvement in allergic drug reactions	15
Epidemiology of the relationship between allergic bronchopulmonary aspergillosis and asthma	14
Transition of care in inborn errors of immunity	13
Perioperative anaphylaxis: when the allergological work-up goes negative	13

Paucity of gastrointestinal plasma cells in common variable immunodeficiency	13
Greater mechanistic understanding of the cutaneous pathogenesis of Stevens–Johnson syndrome/toxic epidermal necrolysis can shed light on novel therapeutic strategies: a comprehensive review	12
LNIT-Local nasal immunotherapy in allergic rhinitis: revisited evidence and perspectives	12
Editorial introductions	12
Is allergen immunotherapy a model of personalized treatment in pediatric respiratory allergy?	12
Health disparities in allergic diseases	12
Updates in diagnosis and management of paediatric mastocytosis	12
Food-labeling issues for severe food-allergic consumers	12
A review of food allergy-related costs with consideration to clinical and demographic factors	12
Editorial introductions	12
Clinical remission in severe asthma: lights and shadows on an ambitious goal	11
Chronic rhinosinusitis with nasal polyps: eosinophils versus B lymphocytes in disease pathogenesis	11
Management and treatment of perioperative hypersensitivity	11
Updates in school-based asthma management	11
Monogenic forms of common variable immunodeficiency and implications on target therapeutic approaches	10
Update on hereditary C1q deficiency: pathophysiology, clinical presentation, genotype and management	10
Food allergy: new therapeutic options open deeper questions	10
Editorial introductions	10
Biomarkers in the diagnosis of mast cell activation	10
Role of the ocular surface microbiome in allergic eye diseases	10
The complexity in DNA methylation analysis of allergic diseases	10
Do bacterial vaccines/adjuvants prevent wheezing episodes in children?	9
Precision allergy molecular diagnosis applications in food allergy	9
Strengthening the case for intralymphatic immunotherapy	9
Atopic dermatitis and ocular allergy: common mechanisms and uncommon questions	9
What's new in pediatric asthma and rhinitis phenotypes and endotypes?	9
Immunobiologicals and ocular surface disease	9
Precision medicine to personalize medicine in allergic airway disease	8
Occupational respiratory allergy to reactive dyes	8
Predictive models and applicability of artificial intelligence-based approaches in drug allergy	8
The role of macrolides in chronic rhinosinusitis and nasal polyps	8
Giant cell arteritis and innovative treatments	8
Neurotrophic keratitis: inflammatory pathogenesis and novel therapies	8
Interstitial lung diseases in inborn errors of immunity	8
Poor statistical reporting: do we have a reason for concern? A narrative review and recommendations	8
Adverse effects of anti-cancer biologics on the ocular surface	8
Access from healthcare professionals to evidence-based pharmacotherapy in allergy management	8
New causes of occupational allergic contact dermatitis	8
Pathology of T-cell-mediated drug hypersensitivity reactions and impact of tolerance mechanisms on patient susceptibility	8
New insights into the diagnosis and management of Stevens–Johnson syndrome and toxic epidermal necrolysis	8
Clinical outcomes of AIT in the elderly population	7
Transgenic murine models for the study of drug hypersensitivity reactions linked to HLA-I molecules	7
Editorial: Pharmacotherapy and evidence based medicine	7
Neurostimulation for dry eye disease	7
Omalizumab is the Columbus egg for food allergies	7
Type-2-low severe asthma endotypes for new treatments: the new asthma frontier	7
New evidence in food allergies treatment	7
The development of the DEFASE project	7
Ocular surface disorders: office procedures for the allergist/clinical immunologist	7
Highlights of the treatment of allergic rhinitis according to Chinese guidelines	7

Editorial introductions	7
The risk of anaphylaxis on holidays	7
Endotypes of occupational asthma	7
Moderate asthma: burden, mechanisms and therapeutic perspectives	7
Diagnostic criteria of chronic conjunctivitis: atopic keratoconjunctivitis and vernal keratoconjunctivitis	7
Role of biologics in severe food allergy	7
MicroCrystalline Tyrosine-adsorbed immunotherapy	7
Editorial introductions	7
An update on patient reported outcomes in type 2 inflammation airway disease	6
Update on aspirin exacerbated respiratory disease with chronic rhinosinusitis	6
Biologics and severe asthma in children	6
Recent advances in the diagnosis and management of tree nut and seed allergy	6
Anaphylaxis in elderly people	6
Editorial introductions	6
Editorial introductions	6
New insights into the mechanisms of aspirin-exacerbated respiratory disease	6
Corneal complications of rheumatoid arthritis	6
Editorial introductions	6
Genetic landscape of atopic dermatitis	6
Editorial introductions	6
Perioperative anaphylaxis: updates on pathophysiology	6
Global patterns of drug allergy-induced fatalities: a wake-up call to prevent avoidable deaths	6
Diagnosis, management and therapeutic options for eosinophilic esophagitis	6
Biologics to treat anaphylaxis	5
Integrative therapeutics for ocular surface disorders	5
Chronic urticaria: not only after COVID-19 vaccination	5
Biologicals in IgE-mediated food allergy	5
Editorial introductions	5
The evolution of cyclosporine treatments for treatment of ocular surface diseases	5
Anaphylaxis: glimpse into the future, attention to the present	5
Advances in gene therapy for inborn errors of immunity	5
Applying the new guidelines to asthma management in children	5
Management of food allergy based on oral food challenge	5
STAT1 and STAT3 gain of function: clinically heterogenous immune regulatory disorders	5
The biological basis for current treatment strategies for granulomatous disease in common variable immunodeficiency	5